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Abstract
Background: Mu ¨ller cell gliosis occurs in various retinal pathologies regardless of the underlying cellular defect. Because
activated Mu ¨ller glial cells span the entire retina and align areas of injury, they are ideal targets for therapeutic strategies,
including gene therapy.
Methodology/Principal Findings: We used adeno-associated viral AAV2/6 vectors to transduce mouse retinas. The
transduction pattern of AAV2/6 was investigated by studying expression of the green fluorescent protein (GFP) transgene
using scanning-laser ophthalmoscopy and immuno-histochemistry. AAV2/6 vectors transduced mouse Mu ¨ller glial cells
aligning the retinal blood vessels. However, the transduction capacity was hindered by the inner limiting membrane (ILM)
and besides Mu ¨ller glial cells, several other inner retinal cell types were transduced. To obtain Mu ¨ller glial cell-specific
transgene expression, the cytomegalovirus (CMV) promoter was replaced by the glial fibrillary acidic protein (GFAP)
promoter. Specificity and activation of the GFAP promoter was tested in a mouse model for retinal gliosis. Mice deficient for
Crumbs homologue 1 (CRB1) develop gliosis after light exposure. Light exposure of Crb1
2/2 retinas transduced with AAV2/
6-GFAP-GFP induced GFP expression restricted to activated Mu ¨ller glial cells aligning retinal blood vessels.
Conclusions/Significance: Our experiments indicate that AAV2 vectors carrying the GFAP promoter are a promising tool for
specific expression of transgenes in activated glial cells.
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Introduction
Mu ¨ller glial cells are the predominant glial cell type of the
vertebrate retina. Mu ¨ller glial cells span the entire thickness of the
retina and are involved in a wide variety of physiological processes
that are vital to proper functioning of the retinal neurons. They
are important in retinal development, provide their neighboring
neurons with metabolic support, maintain retinal ion and water
homeostasis, contribute to the recycling of neurotransmitters as
well as photopigments and protect the neurons against oxidative
stress [1]. In addition to their functions in the healthy retina,
Mu ¨ller glial cells play crucial roles in almost all retinal pathologies,
such as retinal detachment, diabetic retinopathy, inflammation
and glaucoma [1,2]. In response to retinal disease or injury, Mu ¨ller
glial cells are activated. This can eventually lead to gliosis.
Activated Mu ¨ller glial cells exert several neuroprotective activities
that promote the survival of the retinal neurons during stress, such
as the secretion of neurotrophic factors as well as antioxidants [3].
However, the dedifferentiated state of activated Mu ¨ller glial cells
also contributes to neuronal stress due to impairment of their
neurosupportive activities [4]. Because of their crucial role in
retinal disease, Mu ¨ller glial cells are important targets for gene
therapy [5].
Of the viral vectors that have been tested in retinal gene
transfer, those derived from the adeno-associated virus (AAV) are
regarded as most promising [6]. AAV vectors have been used
extensively to transfer genes to the retina in many animal models
for retinal diseases and shown to be useful for the treatment of
genetic defects that affect either photoreceptor cells or retinal
pigment epithelium (RPE) [7]. The efficacy and safety of AAV
vectors has recently been demonstrated in Leber’s congenital
amaurosis (LCA) patients with RPE65 mutations [8–11].
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12387The goal of this study is to obtain a vector system that allows
expression of transgenes only in activated Mu ¨ller glial cells present
at the site of retinal disease or injury. In rats, after intravitreal
injection, AAV2/6 is able to transduce to equal extent retinal
ganglion cells, amacrine, bipolar and Mu ¨ller glial cells, whereas
horizontal and photoreceptor cells were transduced to much lower
extent [12]. When injected intravitreally, the inner limiting
membrane (ILM) might act as a barrier to efficient transduction
of the retina [13]. Depending on the time-point of administration,
intravitreal delivery of AAV vectors results in transduction of a
different set of retinal cell types. For example, more ganglion cells
were transduced by AAV2/2 when delivered to the adult rat retina
compared with delivery at P0 [14]. Moreover, the viral titer and
the promoter used to drive the transgene have great influence on
the level and pattern of expression [15]. All these aspects were
considered in our study as we further optimized the transduction
efficiency of AAV2/6 for mouse glial cells. Our results showed that
AAV2/6 vectors were able to transduce mouse Mu ¨ller glial cells
aligning retinal blood vessels. Additionally, the ILM should be
regarded as a barrier to intravitreally delivered AAV2/6, since
collagenase treatment substantially increased the penetration of
AAV2/6 into the entire retina. The consequence of better AAV2/
6 penetration was the transduction of retinal ganglion cells,
amacrine, horizontal, bipolar and Mu ¨ller glial cells throughout the
retina.
In reaction to retinal damage or cellular defects, retinal Mu ¨ller
glial cells become activated. This activation is characterized by the
induction of glial fibrillary acidic protein (GFAP) and the
downregulation of p27
kip1 and cyclin D3 [2]. Previously, in
transgenic mice, it has been shown that the GFAP promoter can
drive green fluorescent protein (GFP) expression specifically in
Mu ¨ller glial cells and that this expression is induced once the cells
are activated [16]. In this study, by incorporating the GFAP
promoter instead of the commonly used cytomegalovirus (CMV)
or CMV early enhancer/chicken b-actin (CAG) promoters into
AAV2/6 vectors, we aimed to restrict transgene expression to
activated Mu ¨ller glial cells. The Mu ¨ller glial cell-targeted gene
transfer was tested in a mouse model deficient for Crumbs
homologue 1 (CRB1) that exhibits retinal degeneration accompa-
nied by Mu ¨ller cell gliosis. CRB1 encodes a transmembrane
protein that is localized in Mu ¨ller glial cells [17] at the subapical
region (SAR) just above the adherens junctions (AJs) that form the
outer limiting membrane (OLM). The AJs connect the Mu ¨ller glial
cells to the photoreceptor cells. CRB1 is a key component of a
complex of scaffolding proteins involved in stabilization of these
AJs [18]. It has been demonstrated in CRB1-deficient (Crb1
2/2)
mice that the absence of functional CRB1 leads to a loss of
interaction between Mu ¨ller glial cells and photoreceptor cells
which causes retinal disorganization followed relatively late by
retinal degeneration accompanied by Mu ¨ller cell gliosis [19,20].
The retinal degeneration observed in Crb1
2/2 mice corresponds
to that seen in patients with CRB1 mutations, although it is only
observed in one quadrant of the retina [20]. In humans, mutations
in CRB1 are related to LCA and severe forms of retinitis
pigmentosa (RP), which are characterized by progressive retinal
degeneration causing blindness at birth or early adulthood,
respectively [21,22].
By transducing the Crb1
2/2 mouse retina using AAV2/6
vectors in combination with the GFAP promoter, we demonstrate
that it is possible to specifically express transgenes in activated
Mu ¨ller glial cells, without expression in retinal ganglion cells,
amacrine, bipolar, horizontal or photoreceptor cells. Transduced
Mu ¨ller glial cells started to express the GFP transgene when
activated by ciliary neurotrophic factor (CNTF) or injury. These
results suggest that AAV2/6 vectors carrying the GFAP promoter
to drive the expression of neuroprotective or anti-angiogenic
factors might be a promising tool to treat retinal disorders.
Results
Transduction efficiency of AAV2/6
We tested the AAV2/6 serotype on capacity to transduce mouse
retinal cells. Wild-type mice (n=6) received 1 ml of AAV2/6-
CMV-GFP (1.5610
9 genome copies per injection) at three weeks
of age either intravitreally or subretinally. After 21 days, GFP
fluorescence was visualized by scanning laser ophthalmoscopy
(SLO). Figure 1 shows representative images of the fundus
following subretinal or intravitreal injection of the vector
(Fig. 1A, C, E, G). The normal retinal architecture was not
disturbed by vector administration. Following intravitreal injection
in adult mice, GFP expression was detected mainly along the
major retinal blood vessels (Fig. 1B). Subretinal injection
consistently resulted in transduction of a large but restricted part
of the retina (Fig. 1D).
At three months of age, retinas of Crb1
2/2 mice show the first
signs of degeneration [20,23,24]. Structural changes or differences
in gene expression patterns might influence the transduction
characteristics of AAV2/6-CMV-GFP in the Crb1
2/2 retina.
However, at three weeks of age, when there is only a very limited
amount of retinal degeneration, the results in Crb1
2/2 mice (n=6)
were similar to those obtained in wild-type mice (Fig. S1).
To test if injecting at a younger age would increase transduction
efficiency, one day old animals (P1) were intravitreally injected
with 0.5 ml of AAV2/6-CMV-GFP (0.75610
9 genome copies).
Transduction in these young animals was found primarily around
the optic nerve instead of along major blood vessels (Fig. 1F).
Promoter activity might influence the GFP expression pattern.
Hence, we compared the hybrid CMV/b-actin (CAG) promoter
[15] with the CMV promoter. The typical transduction pattern
along the major blood vessels was also observed following
intravitreal injection of AAV2/6-CAG-GFP in three week old
mice (1610
9 genome copies per injection, Fig. 1H).
Histological and flow cytometric analysis
Histological analysis was performed to identify the transduced
cell types. Localization of GFP after intravitreal injection of
AAV2/6-CMV-GFP at three weeks of age is shown in Figure 2A
and revealed the transduction of ganglion cells (asterisk), Mu ¨ller
glial cells (arrow), horizontal, amacrine and bipolar cells (not
indicated). Transduced Mu ¨ller glial cells were easily recognized by
morphological characteristics, as these cells extend from the ILM
to the OLM of the retina having their cell bodies in the inner
nuclear layer (INL). To further corroborate transduction of Mu ¨ller
glial cells (arrow), the sections were stained for the Mu ¨ller glial cell-
specific marker; glutamine synthetase (Fig. 2B). Following
intravitreal injection of AAV2/6-CMV-GFP at P1, mainly
ganglion cells (asterisk) and sporadically photoreceptor cells (arrow
head) close to the optic nerve were found positive for GFP
(Fig. 2C). SLO images at three weeks of age showed that
transduced cells were mainly present in the proximity of larger
blood vessels. The relationship between the blood vessels and
transduced cells is depicted in Figure 2D, showing a blood vessel
surrounded by transduced Mu ¨ller glial cells. In contrast, analysis of
sections from eyes that had received subretinal injections at three
weeks of age revealed that mainly RPE cells were transduced
(Fig. 2E). Other transduced cell types, such as photoreceptor cells
(arrow heads), could be seen only near the site of injection.
Substitution of the CMV for the CAG promoter did not result in
GFAP-Driven Glia Expression
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revealed a relatively high variability in the number of transduced
cells within the examined retinas, but neither the GFP expression
levels nor the number of transduced cells showed statistically
significant difference when comparing the CMV promoter with
the CAG promoter, using the Mann-Whitney test (Fig. 3A and B).
Enhancing the transduction efficiency
The ILM is thinner at the site of the major retinal blood vessels
[25] and is known to be a major obstacle to cell migration after
stem cell transplantation from the vitreal side of the retina [26].
This phenomenon might explain the typical transduction pattern
along the major blood vessels observed following intravitreal
administration of AAV2/6 viral particles. To overcome this
barrier, AAV2/6-CMV-GFP was intravitreally administrated after
disruption of the ILM by collagenase VII treatment [27]. The
integrity of the retinas was studied by SLO (Fig. 4A), which
revealed acute retinal hemorrhage in 2 out of 4 wild-type and all
Crb1
2/2 retinas (data not shown). While the left eye of both wild-
type and Crb1
2/2 mice was left untreated and showed the same
transduction pattern as depicted in Figure 1B, the collagenase-
treated right eye was much more efficiently transduced (Fig. 4B).
Increased transduction was observed in all wild-type and Crb1
2/2
retinas tested (n=4 and n=5, respectively). Immunohistochemical
analysis showed GFP expression throughout the retina, with
expression in many retinal cell types of the inner retina but not in
photoreceptor cells (Fig. 4C). We confirmed the transduction of
Mu ¨ller glial cells by co-staining with antibodies against glutamine
synthetase (Fig. 4D). Transduction profiles were established using
cell type specific markers (for horizontal cells we used Prox1, and
for ganglion and amacrine cells calretinin) comparing transduced
retinas with and without collagenase treatment (Fig. 5A and B). No
significant changes in the transduction profile were found after
collagenase treatment.
Transduction of the human retina
Our ultimate goal is to develop gene therapy to treat human eye
diseases. In order to test whether the AAV2/6 vectors are able to
transduce human retinal cells, we obtained donor eyes from the
Cornea Bank Amsterdam within 48 hours post mortem and
prepared the human retina for culture. The ILM was lifted and
AAV2/6-CMV-GFP particles (1610
9 genome copies) were
injected between the ILM and the neural retina. After 7 days of
culture, GFP expression could be detected as a halo around the
injection site. When the retinas were sectioned, GFP expression
was observed in Mu ¨ller glial cells near the injection site (Fig. 6A) as
well as further away (Fig. 6B). We confirmed the cell type by co-
staining with antibodies against glutamine synthetase (Fig. 6C).
These results show for the first time that not only mouse but also
human Mu ¨ller glial cells can be transduced by AAV2/6.
Restricted transgene expression in activated Mu ¨ller glial
cells
CRB1 is a protein expressed in Mu ¨ller glial cells [17] and
mutations in the CRB1 gene cause LCA. Previously, we evaluated
the Crb1
2/2 mouse as model for CRB1 related eye diseases [20].
Retinal degeneration in Crb1
2/2 mice was observed in only one
quadrant of the retina and occurred in foci. Mu ¨ller glial cells
aligning these foci were activated and expressed GFAP.
Figure 1. SLO of AAV2/6-CMV-GFP transduced wild-type mouse retinas 3 weeks post injection. SLO analysis was performed at 830 (IR)
and 488 (AF) nm on all animals and representative examples are shown. After intravitreal injection of AAV2/6-CMV-GFP at postnatal day 21 (n=6), the
integrity of the retina appeared normal (A) and the fluorescent signal for GFP was detected along the major retinal blood vessels (n=6) (B). After
subretinal injection with AAV2/6-CMV-GFP at postnatal day 21 (n=6), retinal integrity was not affected (C), while the GFP expression was detected at
a restricted part of the retina (D). Intravitreal injection of AAV2/6-CMV-GFP at postnatal day 1 (n=5) did no major damage to the retina (E) and GFP
expression was concentrated at the center of the retina near the optic nerve (F). Intravitreal injection of AAV2/6-CAG-GFP at postnatal day 21 (n=5)
did not harm the retinal integrity (G), while GFP expression was predominantly found along retinal blood vessels (H), comparable to AAV2/6-CMV-
GFP.
doi:10.1371/journal.pone.0012387.g001
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exclusively target Mu ¨ller glial cells, but display tropism for other
neural components of the inner retina (bipolar, amacrine,
horizontal and ganglion cells). Hence, to obtain restricted Mu ¨ller
glia cell transgene expression, we tested the mouse GFAP
promoter [16] in our mouse model for progressive Mu ¨ller cell
Figure 2. Immunohistochemistry on AAV2/6-CMV-GFP transduced wild-type mouse retinas 3 weeks post injection. Examples of
transduced cell types after intravitreal injection of AAV2/6-CMV-GFP at postnatal day 21 (A) and confirmed by colocalization of GFP (green) and
labeling with the Mu ¨ller glia cell marker glutamine synthetase (red) (B). Transduction of mainly ganglion cells near the optic nerve when AAV2/6-
CMV-GFP was injected at postnatal day 1 (C). Mu ¨ller glial cells in the close proximity of a blood vessel (D). GFP expression in RPE and photoreceptors
cells after injecting AAV2/6-CMV-GFP subretinally (P21, E). Transduced cell types found after intravitreal injection of AAV2/6-CAG-GFP at postnatal day
21 (F). Symbols/abbreviations used in panels: Arrow; Mu ¨ller glial cells, Asterisks; ganglion cells, Arrow head; photoreceptor cells, ONL; outer nuclear
layer, OPL; outer plexiform layer, INL; inner nuclear layer, IPL; inner plexiform layer, GCL; ganglion cell layer. Lu; vessel lumen. Scale bars represent
10 mm.
doi:10.1371/journal.pone.0012387.g002
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injection of these viral particles (8610
9 genome copies) in
Crb1
2/2 mice was performed at three weeks of age, when signs
of retinal degeneration were still very limited [20]. Importantly, in
an unaffected wild type or Crb1
2/2 retina, Mu ¨ller glial cells are
not activated and will not express GFAP.
Previously, we described that the Crb1
2/2 phenotype is
enhanced when the retina is exposed for 72 hours to white light
(3000 lux) [20]. The induction of the Crb1
2/2 phenotype was
accompanied by activated Mu ¨ller glial cells that were positive for
GFAP, a phenomenon under the same conditions not observed for
wild type Mu ¨ller glial cells. The same strategy of light exposure
was used on Crb1
2/2 mice following intravitreal injection of
AAV2/6-GFAP-GFP (8610
9 genome copies; n=7). At 10 weeks
after injection, the animals were exposed to white light for
72 hours. No abnormalities in the retina were observed before
light exposure (Fig. 7A) as reflected by the absence of GFAP-
driven GFP expression at 21 days after injection (Fig. 7B). After
light exposure, disturbances occurred in the Crb1
2/2 retinas
(n=7) but not in wild type controls (n=5). When these Crb1
2/2
animals were examined by SLO, four out of seven animals
exhibited GFP-positive spots aligning the major retinal blood
vessels or the injection site (Fig. 7C). A severe form of retinal
degeneration resulting in the loss of retinal integrity detectable by
SLO was observed in one of seven Crb1
2/2 animals analyzed
(Fig. 7D). Histological analysis confirmed a completely disturbed
and degenerated outer nuclear layer (ONL; Fig. 7E). Character-
istic for the Crb1
2/2 phenotype in mice, only one quadrant of the
retina was affected (Fig. 7F) [20]. GFP-positive Mu ¨ller glial cells
could be detected, especially at the border of the degenerated area
(Fig. 7G and H). Mu ¨ller glial cells in the affected area were not
only activated but also disorganized (Fig. 7H, asterisk). It should be
noted though that the observed fluorescence in the SLO originates
not only from the activated Mu ¨ller glial cells, but mostly from
auto-fluorescent signals from deposited cell debris in the disturbed
areas of the ONL (Fig. 7I, arrowheads). This auto-fluorescence
could be distinguished from GFP expression by fluorescence
microscopy of cryostat sections.
Due to the strong variability in the Crb1
2/2 phenotype we
decided to test the GFAP promoter in a different way. At four
weeks after the intravitreal injection with AAV2/6-GFAP-GFP the
integrity of the retina was still intact (Fig. 8A) and no fluorescent
signal could be detected using SLO (Fig. 8B). GFAP expression in
Mu ¨ller glial cells was induced by an intravitreal injection of CNTF
at 28 days after transduction [16,28]. At one day after CNTF
injection a few spots of fluorescence were observed with SLO
(Fig. 8C). While the integrity of the retina was still not
compromised (Fig. 8D and G), more signal was seen at four days
after injection (Fig. 8E and H), In sections, GFP-positive Mu ¨ller
glial cells were detected aligning the major retinal blood vessels
(Fig. 8F). Importantly, no GFP-positive ganglion, amacrine,
bipolar, horizontal, or photoreceptor cells were detected. Thus,
in contrast to GFP expression found in multiple retinal cell types
following transduction with an AAV2/6 vector that contains a
CMV promoter (Fig. 2A), AAV2/6-GFAP-GFP targets transgene
expression specifically to activated Mu ¨ller cells. The cells
expressing GFP were indeed Mu ¨ller glial cells since they were
positive for glutamine synthetase (Fig. 8I). The number of GFP
expressing cells is quite limited due to the fact that only Mu ¨ller
glial cells in the proximity of major retinal blood vessels were
transduced with AAV2/6-GFAP-GFP of which only some became
activated by CNTF. These results suggest that AAV2/6 vectors
carrying the GFAP promoter are suitable for expressing genes of
interest specifically in Mu ¨ller glial cells close to retinal blood vessels
at the site of retinal degeneration. Furthermore, the transgene will
only be expressed in Mu ¨ller glial cells when they become activated.
Discussion
Here we showed that, retinal ganglion, amacrine, bipolar and
Mu ¨ller glial cells in the proximity of major retinal blood vessels
were transduced by AAV2/6-CMV-GFP and showed reporter
gene expression. Additionally, using AAV2/6-GFAP-GFP, we
showed stress- or injury-dependent GFAP-driven gene expression
limited to activated Mu ¨ller glia cells aligning the major retinal
blood vessels.
Figure 3. Flow cytometric analysis of AAV2/6-CMV-GFP vs
AAV2/6-CAG-GFP transduced retinas. Representative example of
7-AAD staining; the negative (live) population is used for further
analysis (A). A representative comparison of retinal cells from eyes
transduced via intravitreal injection of either AAV2/6-CMV-GFP (blue) or
AAV2/6-CAG-GFP (red) resulted in a population of GFP-positive cells.
The left edge of the gate for GFP-positive cells was set using non-
transduced retinal cells (gray) (B). The inset shows the mean (+SEM) of
the fraction of the live cells that are GFP-positive in CAG-GFP compared
to CMV-GFP eyes (n=5). These measurements show no statistically
significant differences (p.0.6, Mann-Whitney test).
doi:10.1371/journal.pone.0012387.g003
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cellular defect Mu ¨ller glial cells become activated [1]. Since they
span the entire retina and align the sites of injury, activated Mu ¨ller
glia cells might be the optimal ‘‘factory’’ for secreted proteins that
protect the surrounding neurons [29–31]. In this study, we aimed
to generate an AAV-based vector system to specifically express
transgenes in activated Mu ¨ller glial cells. By using AAV2/6
containing the Mu ¨ller glial cell-specific GFAP promoter, we
achieved transgene expression that is selectively targeted to
activated Mu ¨ller glial cells aligning the major retinal blood vessels.
We thereby aligned transgene expression with affected areas of the
retina, in a mouse model of retinal degeneration with extensive
Mu ¨ller glial cell activation.
AAV2/6-mediated transduction of rat Mu ¨ller glial, ganglion,
bipolar and amacrine cells has previously been demonstrated [12],
but the expression was not reported to be limited to Mu ¨ller cells
aligning the major blood vessels. Here, we set out to optimize
AAV2/6-mediated transduction of mouse Mu ¨ller glial cells.
Following intravitreal administration in the adult mouse, AAV2/
6-CMV-GFP was able to transduce Mu ¨ller glial, ganglion, bipolar,
horizontal and amacrine cells aligning the blood vessels. In a
clinical setting, intravitreal injections would be the preferred route
of administration for several reasons. Firstly, intravitreal admin-
istration would be potentially less deleterious to an already
weakened and diseased retina [32,33]. Secondly, viral particles can
spread more easily when delivered via the intravitreal route
allowing a wider area of retinal transduction. Surprisingly,
transduction by AAV2/6 was mainly seen along the major retinal
blood vessels. As for other AAV serotypes [13] and stem cells [26],
the ILM proved to be a barrier for AAV2/6 penetration into the
retina. Since the human ILM is much thicker we decided to lift the
ILM of human retina explants and apply the viral vectors under
the ILM. Following this procedure we were able to transduce
human Mu ¨ller glial cells with AAV2/6. While collagenase
treatment is not applicable to patients, ILM peeling or lifting is
[34] and might be used as a way to administer AAV2/6 to the
human retina in order to transduce human Mu ¨ller glial cells. Hata
et al [35] demonstrated that the intravitreal route and the
subretinal route are not harmful to the function and appearance of
the retina. Moreover, they showed that ILM peeling in the
Figure 4. The ILM forms a barrier for efficient Mu ¨ller glial cell transduction by AAV2/6-CMV-GFP. Representative images of SLO at
830 nm (A) and 488 nm (B) and of fluorescence microscopy for GFP expression (C and D) are shown for retinas after intravitreal injection of AA2/6-
CMV-GFP in collagenase treated wild-type eyes (n=4) at three weeks post injection. The integrity of the retinas appeared normal in most cases (A).
GFP expression was detected throughout the whole retina (B). Sections of the retina reveal transduction of Mu ¨ller glial cells, ganglion, amacrine,
horizontal and bipolar cells (C). The cell type was confirmed by double labeling with the Mu ¨ller glial cell marker glutamine synthetase (red) (D).
Symbols/abbreviations used in panels: Arrow; Mu ¨ller glial cells, Asterisks; ganglion cells, OLM; outer limiting membrane, ONL; outer nuclear layer, OPL;
outer plexiform layer, INL; inner nuclear layer, IPL; inner plexiform layer, GCL; ganglion cell layer. Scale bars represent 10 mm.
doi:10.1371/journal.pone.0012387.g004
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on the appearance of the retina. In this study, we did not assess
whether in vivo AAV2/6 transduces human Mu ¨ller glia cells
aligning the major blood vessels, as is the case in the mouse retina.
Expression limited to Mu ¨ller glia cells aligning the major blood
vessels could however be of potential advantage for expressing
drugs locally that currently are systemically administered. E.g.
Mu ¨ller glia cells could be used to express and secrete VEGF
inhibitors in the retina of patients with age related macula
degeneration, or other drugs that prevent neovascularization in
the retina of patients with retinal dystrophy. Whilst we used
AAV2/6 to transduce Mu ¨ller glial cells aligning the major blood
vessels, recently other AAV capsids generated via directed
evolution have been shown to be more potent transducers of rat
astrocytes and retinals cells [36]. One AAV6 variant (ShH10)
showed efficient and selective transduction of rat Mu ¨ller cells
throughout the retina, not limited to Mu ¨ller cells aligning the
major blood vessels [37]. Future experiments might demonstrate
their potential to transduce human Mu ¨ller glial cells.
GFAP is a intermediate filament protein present in Mu ¨ller glial
cells, astrocytes, microglia, and Schwann cells that is upregulated in
activated cells in reaction to injury [1]. GFAP is not only
upregulated, but also actively involved in the morphological
changes of Mu ¨ller glial cells that follow experimental retinal
detachment [33] and age-related macular degeneration (AMD)
[38]. Even retinal detachment caused by a subretinal injection gave
rise to activation of Mu ¨ller glial cells as reflected by detectable
GFAP expression levels at 28 days after injecting a balanced salt
solution [39]. The GFAP promoter appeared effective in expressing
GFP as transgene in activated Mu ¨ller glial cells of the degenerating
rat retina, when delivered subretinally by lenti-viral vectors [40].
Here, we delivered the GFAP promoter and GFP transgene to
mouse Mu ¨ller glial cells aligning the major retinal blood vessels via
intravitreal injection of AAV2/6-GFAP-GFP. The advantage of the
intravitreal administration route is the absence of Mu ¨ller glial cell
activation [28] as was confirmed by the absence of fluorescent signal
at 21 days after injection of AAV2/6-GFAP-GFP.
Figure 5. Transduction profiles of AAV2/6-CMV-EGFP retinas with or without collagenase treatement. Representative retinal slices from
injected eyes were quantified for the number of each transduced cell type. Specific markers were used to determine the different cell types and to
generate histograms comparing tropism profiles with (B) and without collagenase treatment (A). Transduction efficiencies were calculated based on
the ratio of each cell type infected relative to the total number of EGFP-positive cells (n=9). Error bars represent standard deviation among sample
population.
doi:10.1371/journal.pone.0012387.g005
Figure 6. Transduction of human cultured retinas with AAV2/6-
CMV-GFP. Retinas were prepared from donor eyes and transduced
with AA2/6-CMV-GFP, by injection of 1 ml viral particle suspension
under the ILM. Retinas were cultured for 7 days (n=2), followed by
fluorescence microscopic analysis of cryostat sections (10 mm). GFP-
positive Mu ¨ller glial cells (green signals) were found near the injection
site (A) as well as further away (B). The cell type was confirmed by
double labeling with the Mu ¨ller glial cell marker glutamine synthetase
(red) (C). Symbols/abbreviations used in panels: Arrow; Mu ¨ller glial cells,
OLM; outer limiting membrane, ONL; outer nuclear layer, OPL; outer
plexiform layer, INL; inner nuclear layer, IPL; inner plexiform layer, GCL;
ganglion cell layer.
doi:10.1371/journal.pone.0012387.g006
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expression via the stress-inducible GFAP-promoter allows endog-
enous modulation. Mu ¨ller glial cells were activated using two
different approaches: intravitreal administration of ciliary neuro-
trophic factor (CNTF) and light exposure to CRB1 deficient mice.
The yield of the activated Mu ¨ller glial cells expressing the
Figure 7. Light-induced GFP expression in AAV2/6-GFAP-GFP transduced Crb1
2/2 Mu ¨ller glial cells. Crb1
2/2 mice, three weeks of age,
were intravitreally injected with AAV2/6-GFAP-GFP (8610
9 genome copies; n=3). At 21 days after injection, before light exposure, retinal
degeneration and fluorescence were analyzed by SLO at 830 nm (A) and 488 nm (B), respectively. 10 weeks after transduction the mice were
exposed to white light (3000 lux) for 72 hours. GFAP-driven GFP expression was detected by SLO in Crb1
2/2 mice (n=7) (C). One out of seven
Crb1
2/2 animals showed severe retinal degeneration on SLO analysis as reported before [20,24] (D). The retinas showed extensive fluorescence in
one quadrant of the retina (F). In the severely affected retina (E), most GFP and glutamine synthetase positive Mu ¨ller glial cells were found at the
border of the area of ONL degeneration (G and H). Slices adjacent to the one showing the overview in E were subjected to immunohistochemistry
with antibodies against glutamine synthetase. G’, H’ and I’ are the positions of the figures G, H and I taken from adjacent slices to the overview shown
in E. The asterisk in (H) points at the abnormal structure of the activated Mu ¨ller glial cells and glial scar formation. In the middle of the degenerative
area, the ONL is completely lost (E). In this area, highly auto-fluorescent patches of cell debris, indicated by arrowheads (I), accounted for most of the
fluorescent signal found on SLO. Symbols/abbreviations used in panels: Arrow; Mu ¨ller glial cells, ONL; outer nuclear layer, INL; inner nuclear layer, IPL;
inner plexiform layer, GCL; ganglion cell layer.
doi:10.1371/journal.pone.0012387.g007
GFAP-Driven Glia Expression
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12387transgene was low due to the fact that only 3% of the total retinal
cells were transduced by intravitreal injection of AAV2/6 without
removing the ILM (Fig. 3). Mu ¨ller glial cells make up only 15% of
the transduced cells (Fig. 5) and with 3 days of light exposure or 4
days after CNTF administration not all transduced Mu ¨ller glial
cells became activated [20,28]. Different approaches as ILM
peeling or lifting in a human setting or using the AAV6 variant
(ShH10) [37] to deliver the GFAP driven transgene might increase
the yield of activated Mu ¨ller glial cells expressing the transgene.
Mice lacking CRB1 showed upregulation of GFAP before onset
of retinal disorganization and degeneration [20]. For gene therapy
using trophic factors (e.g. GDNF), it might be very important that
the therapeutic transgene is not continuously expressed but
modulated along with severity of the pathology. This requirement
Figure 8. CNTF-induced GFP expression in AAV2/6-GFAP-GFP transduced Mu ¨ller glial cells. 3-week-old Crb1
2/2 mice were intravitreally
injected with AAV2/6-GFAP-GFP (8610
9 genome copies; n=3). Three weeks after injection, the integrity of the retina appeared normal on SLO (A). No
GFP signal was observed (B). At 28 days after transduction, eyes were re-injected intravitreally with CNTF. GFAP-driven GFP expression was detected
by SLO at one day (C) and four days (E and H) after administration of CNTF. Secondary injections did not affect the retinal integrity (D and G).
Activated Mu ¨ller glial cells expressing GFP were found on sections (10 mm) of the CNTF challenged eyes (F) and immuno-histochemistry confirmed
the cell type as colocalization with glutamine synthetase was demonstrated (I). Symbols/abbreviations used in panels: Arrow; Mu ¨ller glial cells OLM;
outer limiting membrane, ONL; outer nuclear layer, OPL; outer plexiform layer, INL; inner nuclear layer, IPL; inner plexiform layer, GCL; ganglion cell
layer.
doi:10.1371/journal.pone.0012387.g008
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drive the transgene expression in activated Mu ¨ller glial cells. The
AAV2-GFAP vector system might now be used to deliver various
molecules to retinas with different types of disease or injury to test
their therapeutic potency.
Materials and Methods
Animals
All procedures concerning animals adhered to the ARVO
statement for the use of animals in ophthalmic and vision research,
and were performed with permission of the animal experimenta-
tion committee (DEC) of the Royal Netherlands Academy of Arts
and Sciences (KNAW), permit number NIN08-17. The generation
of the Crb1
2/2 mice was described previously [20]. All mice used
were maintained on a 50% C57BL/6 and 50% 129/Ola genetic
background. Except for the light-exposed mice, animals were
maintained on a 12 h day/night cycle and supplied with food and
water ad libitum.
Generation and purification of the viral vectors
The plasmids used to generate the AAV vectors were derived
from plasmid pTRCGW and consist of the inverted terminal
repeats (ITRs) of AAV2, the CMV, CAG or GFAP promoter, the
cDNA encoding GFP, the simian virus 40 (SV40) polyadenylation
signal and the woodchuck post-transcriptional regulatory element.
The CMV promoter in the original plasmid was replaced by a
2.6 kb mouse GFAP promoter fragment [16]. AAV stocks were
generated and purified as described previously [41]. Briefly,
plasmids containing the transgene flanked by the ITRs were co-
transfected with the AAV2/6 helper plasmid pDP6 (Plasmid
Factory, Bielefeld, Germany) into HEK293T cells to generate
cross-packaged AAV2/6 viral vectors [12,36]. At the third day
after transfection, the medium was changed for lysis buffer
(50 mM Tris, 2 mM MgCl2, 150 mM NaCl and 0.1% Triton X-
100). After DNAse treatment, the crude lysate was loaded onto an
iodixanol density gradient (Sigma, St Louis, Mo, USA) and
centrifuged for 70 min in a Beckman XL-100K ultracentrifuge at
69000 rpm at 16uC [42]. Fractions containing the viral vectors
were collected and concentrated using Amicon Ultra-15 concen-
trators. All viral titers were determined by q-PCR and all viral
stocks with titers above 1610
12 genome copies/ml were stored at
280uC until use.
Intravitreal and subretinal injections
Three-week-old mice were anesthetized with 100 mg/kg
ketamine and 5 mg/kg xylazine i.p. Their pupils were dilated
with eye drops that contain 5 mg/ml tropicamide (Chauvin
Benelux, Brussels, Belgium). To prevent dehydration of the
cornea, the eyes were treated with viscotears (Novartis Pharma,
Arnhem, The Netherlands). The mice were placed on a heating
pad to maintain their body temperature at 37uC during the whole
procedure. Subsequently, 1.5610
9 genome copies of vector in 1 ml
were either subretinally or intravitreally injected using a 33 gauge
needle (Hamilton, Bonaduz, Switzerland). The mice were allowed
to recover and their eyes were treated with 10 mg/g chloram-
phenicol (Ratiopharm, Zaandam, The Netherlands) to prevent
infections. Intravitreal injections were done with and without
disruption of the ILM by collagenase treatment [27]. For
collagenase treatment, mice were anesthetized by inhalation of
isoflurane (5%). Following dilation of their pupils, 1 mlo f
collagenase type VII (50 units/ml; Sigma-Aldrich, Zwijndrecht,
The Netherlands) was intravitreally injected into the right eye. The
left eye was not injected. Seven hours after the collagenase
injection, the mice were anesthetized again (ketamine and
xylazine). Their pupils were dilated and 0.5610
9 genome copies
of vector in 1 ml containing laminin and a2-macroglobulin (1 mg/
ml each; both Sigma-Aldrich) were intravitreally injected into both
eyes.
Mice intravitreally injected with viral vectors carrying the GFAP
promoter were either additionally intravitreally injected with
0.5 ml of 1 mg/ml CNTF at 28 days after viral transduction or
exposed to white light at 10 weeks after viral transduction.
Light exposure
The animals were placed in a white box and continuously
exposed to diffuse white light of 3000 lux (TLD-18W/33tubes,
Philips; 350-700 nm) for 72 h without pupillary dilation. Imme-
diately after these 72 h of light exposure the animals were
anesthetized and subjected to scanning-laser ophthalmoscopy
(SLO).
Scanning-laser ophthalmoscopy
Three weeks after injection of the viral vector, the mice were
anesthetized by ketamine and xylazine i.p. Dilation of their pupils
was done with eye drops containing 50 mg/ml phenylephrine HCl
(The ´a Pharma, Zoetermeer, The Netherlands). To prevent
dehydration of the cornea, the eyes were treated with Methocel
(CIBA Vision, Breda, The Netherlands). SLO was performed with
the Heidelberg Retina Angiograph 2 (HRA 2; Heidelberg
Engineering, Heidelberg, Germany) as described previously [43].
A solid state laser at 488 nm was used to excite GFP. Separation of
excitation and fluorescent light was done with a barrier filter at
500 nm. Infrared reflectance images were generated using a diode
laser at 830 nm.
Immunohistochemical analysis, fluorescence microscopy
and cell counting
The anaesthetized mice were sacrificed by cervical dislocation
immediately after SLO imaging. Their eyes were collected, fixed for
30 min in 4% paraformaldehyde in PBS (pH 7.4) and cryopro-
tected by subsequent incubations of 30 min in 5 and 30% sucrose.
After cryoprotection, the eyes were embedded in Tissue-Tek
(Sakura, Zoeterwoude, The Netherlands), frozen and stored at
280uC. Sections of 7 mm were generated with a Leica CM3050
cryostat (Leica Microsystems, Rijswijk, The Netherlands), mounted
onto SuperFrost Plus glass slides (Menzel-Gla ¨ser, Braunschweig,
Germany) and air-dried. The sections were either enclosed
immediately in Mowiol 4–88 (Sigma-Aldrich) supplemented with
Hoechst 33258 (Invitrogen, Breda, The Netherlands) to counter
stain the cell nuclei or used for immunohistochemical analysis.
Sections used for immunohistochemical analysis [44] were
rehydrated in PBS and blocked for 1 h in 10% normal goat serum
(Jackson ImmunoResearch, Suffolk, UK), 0.4% Triton X-100 and
1% bovine serum albumin (BSA) in PBS. The sections were then
incubated overnight (4uC) with mouse anti-glutamine synthetase
IgGs (1:300; BD Biosciences, Breda, The Netherlands) or anti-GFP
IgGs (1:300; Chemicon, Hampshire, UK) or rabbit anti-Prox1
(1:500; ABCam Ltd, Cambridge, U.K.), or rabbit anti-calretinin
(1:500;ABCamLtd,Cambridge,U.K.)dilutedin0.3%normal goat
serum, 0.4% Triton X-100 and 1% BSA in PBS. After washing the
sections three times with PBS, they were incubated for 1 h with
Cy3-conjugated goat anti-mouse IgGs (Jackson ImmunoResearch)
diluted in 1% BSA in PBS. The sections were washed three times
with PBS and enclosed in Mowiol 4–88 with Hoechst 33258. The
GFP as well as the Cy3 signal was visualized with a Leica DMRE
fluorescence microscope (Leica Microsystems).
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GFP-positive cells, defined by their typical morphology and by co-
labeling with Hoechst 33258 (Invitrogen) and anti-glutamine
synthetase or anti-Prox1 or anti-calretinin. At least three different
sections from each eye within three independent experiments
(n=9/group) were counted at 640 magnification. The number of
GFP-positive cells was divided by the total number of cells present
in the same 640 magnified area to obtain the percentage of
transduced cells. The percentage of transduced cells from each
group was then averaged and standard errors were calculated.
Flow cytometric analysis
Neural retina was isolated from enucleated eyes by dissection of
the anterior part of the eye and attached vitreous from the eye cup,
following a transscleral incision. Individual retinae were incubated
in 1.2 ml of enzyme incubation buffer (4 g/l MgCl2, 2.55 g/l
CaCl2, 3.73 g/l KCl, 8.95 g/l NaCl, pH 6–7) containing 92.5 U
Collagenase I (Worthington, Lakewood NJ, USA) and 0.25 mg
DNase I (Roche, Mannheim, Germany) for 1 hour at 37uC. The
tissue was triturated every 10–12 minutes using a Gilson p1000
pipet and tips with decreasing bore size. Cell suspensions were
washed in 20 ml cell suspension buffer (8 g/l NaCl, 0.4 g/l KCl,
1.41 g/l NaHPO4 anhydrous, 0.69 g/l NaH2PO4.H2O, 2 g/l D-
glucose, pH 7.4, containing 0.2% BSA) and cells recovered in a
pellet following centrifugation at 1,7006g for 10 minutes. For flow
cytometric analysis an equivalent of a tenth of one retina was used
per staining procedure. Cell suspensions were stained by adding
2.5 ml 7-AAD solution (BD Biosciences, San Jose CA, USA) to
100 ml cell suspension 10 minutes before analysis. Flow cytometric
analysis was performed using a FACSCalibur (BD Biosciences),
and data was analyzed using FlowJo (Mac V8.8.6; Tree Star,
Ashland OR, USA). Statistical analysis of the data was performed
with Prism 4.0 for Macintosh, using the Mann-Whitney test for the
analysis of the percentages of GFP positive cells of the 7-AAD
negative population, and the mean fluorescence intensity.
In vitro transduction of the human retina
Human donor eyes were acquired from the Dutch Cornea Bank
Amsterdam and were processed within 48 h after death. Retinas
were dissected free from the posterior eyecup and placed in a
sterile dish. The vitreus was removed as much as possible using
scissors. The ILM was then lifted with a 20ga V-LanceH hook
(Alcon laboratories, Forth Worth, TX, USA) and 1 ml containing
1610
9 genome copies of AAV2/6-CMV-GFP was injected under
the ILM. The retina was cultured for 7 days according to the
previously described protocol for culturing mouse retina explants
[17]. After 7 days, the retinas were fixed for 30 min in 4%
paraformaldehyde in PBS (pH 7.4) and cryoprotected by subse-
quent incubations of 30 min in 5 and 30% sucrose. They were
stored at 280uC until further use.
Supporting Information
Figure S1 SLO of AAV2/6-CMV-GFP transduced Crb1
2/2
mouse retina at 3 weeks post injection. After intravitreal injection
of AAV2/6-CMV-GFP at postnatal day 21 (n=6), the integrity of
the retina appeared normal (A). The fluorescent signal for GFP
was detected along the major retinal blood vessels (B). After
subretinal injection of AAV2/6-CMV-GFP at postnatal day 21
(n=6), the integrity appeared normal (C). GFP fluorescence was
detected along the major retinal blood vessels (D).
Found at: doi:10.1371/journal.pone.0012387.s001 (2.32 MB TIF)
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